Clinical trials

4

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Coercive Control and Intimate Partner Violence

Coercive control (CC) is increasingly recognized as a central component of intimate partner violence (IPV) and a major determinant of victims' health outcomes. While widely integrated into policy and legal frameworks in several countries, CC remains insufficiently explored in the French research context, particularly regarding its clinical and psychopathological dimensions. This gap may limit the identification of victims and the provision of appropriate care. The present study aims to investigate the association between exposure to coercive control and physical and mental health outcomes among victims of intimate partner violence. By improving the understanding of CC-related health impacts, this research seeks to support better identification of high-risk situations and inform clinical and public health interventions.

Participants needed: 250
Trial details
Age: 18+Biological sex: FemaleType: InterventionalSponsor: Centre Hospitalier Intercommunal Robert BallangerUpdated: May 26, 2026Locations: 1
Eligibility criteria

Women aged 18 years and older, who have experienced an intimate partner relation... [+4]

Individuals under legal protection in accordance with the French Public Health C... [+2]

Status: Not yet recruiting

Evaluation of A-DIVA Score Effectiveness at Admission for Preserving Venous Capital in Patients With Difficult Access

In certain cases (e.g.: patient who are difficult to perfuse, thin veins, etc.), an increase in venipunctures performed by study nurses in healthcare services can lead to a loss of venous capital, repeated pain during punctures, discontinuous treatment follow-up and numerous requests for assistance from colleagues, including nurse anesthetists, but often too late. The main objective of project is to reduce the number of punctures to access the venous system after evaluation of adult patients upon entering the hospitalization department using the A-DIVA tool. the A-DIVA score predicts the difficulty in infusing an adult patient

Participants needed: 600
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Centre Hospitalier Intercommunal Robert BallangerUpdated: May 1, 2025Locations: 1
Eligibility criteria

Male and Female Adult Patients Aged 18 Years and Older [+2]

Patients in Intensive Care Units [+9]

Status: Recruiting

Evaluation of the Videodrama Therapeutic Device for Children With Autism Spectrum Disorders

Autism spectrum disorder (ASD) is a neurodevelopmental disorder (Valerie, Sperenza, 2009) that begins early in development, characterized by persistent deficits in communication and social interactions across various contexts and restricted, repetitive patterns of behavior, interests, or activities. These symptoms significantly impact social, school/professional functioning, or other important areas and are not better explained by intellectual disability or global developmental delay (American Psychiatric Association, 2013).

Participants needed: 30
Trial details
Age: 3-15Biological sex: AllType: InterventionalSponsor: Centre Hospitalier Intercommunal Robert BallangerUpdated: Feb 6, 2025Locations: 1
Eligibility criteria

Children aged 3 to 15 years. [+7]

No ASD diagnosis. [+5]

Status: Recruiting

Influence of Preoperative Immunomodulation by Oral Impact on Postoperative Complications Following Cystectomies & Nephrectomies

any studies have shown the benefit of perioperative Oral Impact immunomodulation in gastrointestinal, ENT, gynecological and cardiac surgery. Studies in major Urological surgery are rare and not very contributory. The expected benefit is a reduction in postoperative complications and the average length of stay.

Participants needed: 214
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Centre Hospitalier Intercommunal Robert BallangerUpdated: Jul 15, 2024Locations: 2
Eligibility criteria

18 years of age and older [+3]

Immune deficiency. [+6]